摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-1-(piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one

中文名称
——
中文别名
——
英文名称
(E)-1-(piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
英文别名
N-(3,4,5-trimethoxy cinnamoyl)-piperazine;1-(Piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one;(E)-1-piperazin-1-yl-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
(E)-1-(piperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one化学式
CAS
——
化学式
C16H22N2O4
mdl
——
分子量
306.362
InChiKey
ZQXXBLADSLNAAT-SNAWJCMRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    60
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents
    作者:Xiaojing Li、Jie Ding、Ning Li、Wenxia Liu、Fuhao Ding、Huijuan Zheng、Yanyan Ning、Hongmin Wang、Renmin Liu、Shaoda Ren
    DOI:10.1016/j.ejmech.2019.06.086
    日期:2019.10
    of celastrol derivatives with cinnamamide chains were synthesized and evaluated for their anti-ovarian cancer activities. Most of the compounds exhibited stronger antiproliferative activity than celastrol, and celastrol derivative 7g with a 3,4,5-trimethoxycinnamamide side chain was found to be the most potent antiproliferative agent against ovarian cancer cells with an IC50 value of 0.6 μM. Additionally
    卵巢癌与高百分比的肿瘤复发和对化学疗法的抗性有关。癌症干细胞(CSC)负责癌症的进展,肿瘤的复发,转移和化学耐药性。因此,在癌症研究和临床应用中迫切需要开发靶向CSC的疗法。为了获得有效和选择性的抗-CSC药物,合成了一系列具有肉桂酰胺链的Celastrol衍生物,并评估了它们的抗卵巢癌活性。大多数化合物显示出比celastrol更强的抗增殖活性,并且发现具有3,4,5-三甲氧基肉桂酰胺侧链的celastrol衍生物7g是针对卵巢癌细胞的最有效的抗增殖剂,IC 50为50值为0.6μM。另外,化合物7g显着抑制集落形成能力并减少了肿瘤球的数量。此外,化合物7g降低了CD44 +,CD133 +和ALDH +细胞的百分比。因此,化合物7g是一种有前途的抗CSC药物,可以作为开发新的抗卵巢癌药物的候选药物。
  • Novel cinnamic amides
    申请人:Wellner Eric
    公开号:US20050192289A1
    公开(公告)日:2005-09-01
    E-cinnamic amides of piperazine derivatives according to formula (I) wherein X is chloro or fluoro and R 1 is an aromatic or heteroaromatic group, their pharmaceutically acceptable salts or solvates. The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.
    根据公式(I),X为氯或氟,R1为芳香或杂芳基的哌嗪衍生物的E-肉桂酰胺,其药学上可接受的盐或溶剂。该发明还涉及含有公式(I)化合物的药物组合物,以及制备公式(I)化合物的方法,以及通过向哺乳动物施用具有公式(I)的化合物来治疗患有炎症、自身免疫、增殖性或过度增殖性疾病的方法。
  • Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors
    作者:Cheng-Zhi Gao、Wei Dong、Zhi-Wen Cui、Qiong Yuan、Xia-Min Hu、Qing-Ming Wu、Xianlin Han、Yao Xu、Zhen-Li Min
    DOI:10.1080/14756366.2018.1530224
    日期:2019.1.1
    stronger than neostigmine (12.01 ± 0.45 μM) and exhibited selectivity for BChE over AChE to some degree. Molecular docking studies indicated that 5l could bind simultaneously to the catalytic active of PARP-1, but it could not interact well with huBChE. For pursuit of PARP-1 and BChE dual-targeted inhibitors against AD, small and flexible non-polar groups introduced to the compound seemed to be conducive
    抽象的 设计并合成了一系列新的Olaparib衍生物,并评估了它们在体外对聚(ADP-核糖)聚合酶-1(PARP-1)酶和癌细胞系MDA-MB-436的抑制活性。结果表明,化合物5l对PARP-1酶(16.10±1.25 nM)和MDA-MB-436癌细胞(11.62±2.15μM)表现出最强的抑制作用,接近于Olapaparib。由于据报导PARP-1抑制剂对神经保护具有可行性,为了寻找新的多靶标定向配体(MTDL)来治疗阿尔茨海默氏病(AD),因此合成化合物对AChE酶的抑制活性(还检测了电鳗和马血清中的BChE。化合物5l表现出适度的BChE抑制活性(9.16±0.91μM),比新斯的明(12.01±0.45μM)强,并且在一定程度上对BChE的选择性超过AChE。分子对接研究表明5l可以同时结合PARP-1的催化活性,但不能与huBChE很好地相互作用。为了追求针对AD的PARP-
  • N,N+hu 1 +l SUBSTITUTED PIPERAZINES HAVING COMBINED ANTIAGGREGANT, ANTICOAGULANT AND VASODILATORY ACTIVITY, AND METHOD FOR PRODUCING SAME
    申请人:Veselkina Olga Sergejevna
    公开号:US20130267707A1
    公开(公告)日:2013-10-10
    The invention relates to derivatives of N,N′-substituted piperazines of the general formula (I): where R 1 and R 2 denote linear or branched (C 1 -C 4 )alkyl, linear or branched (C 1 -C 4 )alkoxy, CH 3 C(═O)O or halogen; n=1-5; m=0-3; Z denotes CH 2 , C═O or SO 2 ; X denotes C(═NH)NH 2 , C(═NH)NHC(═NH)NH 2 or CH 2 (CHR 3 ) p CH 2 SO 3 H, where R 3 denotes H, OH, CH 3 C(═O)O or HOSO 2 O and p=0-1; and G denotes low-molecular-weight organic or mineral acid, sodium, potassium or ammonium cations, or water. Said derivatives have antiaggregant, anticoagulant and vasodilatory properties. The invention further relates to a method for producing said derivatives by reacting N-substituted piperazines either with carboxamide amidating agents or salts thereof, or with haloalkyl sulfonic acids or salts thereof in organic solvents or in water in the presence of bases. The compounds may be used for the prophylaxis and treatment of disorders of the hemostatic system.
    该发明涉及一般式(I)的N,N′-取代哌嗪衍生物,其中R1和R2表示线性或支链(C1-C4)烷基,线性或支链(C1-C4)烷氧基,CH3C(═O)O或卤素;n=1-5;m=0-3;Z表示CH2,C═O或SO2;X表示C(═NH)NH2,C(═NH)NHC(═NH)NH2或CH2(CHR3)pCH2SO3H,其中R3表示H,OH,CH3C(═O)O或HOSO2O,p=0-1;G表示低分子量有机或矿物酸,钠,钾或铵阳离子,或水。所述衍生物具有抗凝、抗凝血和扩血管作用。该发明还涉及一种通过将N-取代哌嗪与羧酰胺化剂或其盐,或卤代烷磺酸或其盐在有机溶剂或水中在碱的存在下反应而制备所述衍生物的方法。这些化合物可用于预防和治疗止血系统疾病。
  • Synthesis and discovery of 18β-glycyrrhetinic acid derivatives inhibiting cancer stem cell properties in ovarian cancer cells
    作者:Xiaojing Li、Yihua Liu、Na Wang、Yuyu Liu、Shuai Wang、Hongmin Wang、Aihua Li、Shaoda Ren
    DOI:10.1039/c9ra04961d
    日期:——

    18β-glycyrrhetinic acid derivatives containing cinnamamide moiety could inhibit cancer stem cell properties in ovarian cancer cells.

    18β-甘草酸衍生物含有肉桂酰胺基团,可以抑制卵巢癌细胞中的癌干细胞特性。
查看更多